ILMD, Instituto Leônidas and Maria Deane, 476, Teresina Street, 69057-070 Manaus, AM, Brazil.
BMC Infect Dis. 2014 Jan 30;14:49. doi: 10.1186/1471-2334-14-49.
Immunoassays for Plasmodium detection are, presently, most frequently based on monoclonal antibodies (MAbs); Polyclonal antibodies (PAbs), which are cheaper to develop and manufacture, are much less frequently used. In the present study we describe a sandwich ELISA assay which is capable of detecting P. vivax Lactate Dehydrogenase (LDH) in clinical blood samples, without cross reacting with those infected with P. falciparum.
Two recombinant proteins were produced from different regions of the P. vivax LDH gene. Two sandwich ELISA assay were then designed: One which uses mouse anti-LDH 1-43aa PAbs as primary antibodies ("Test 1") and another which uses anti-LDH 35-305aa PAbs ("Test 2") as the primary antibodies. Rabbit anti-LDH 1-43aa PAbs were used as capture antibodies in both ELISA assays. Blood samples taken from P. vivax and P. falciparum infected patients (confirmed by light microscopy) were analysed using both tests.
"Test 2" performed better at detecting microscopy-positive blood samples when compared to "Test 1", identifying 131 of 154 positive samples (85%); 85 positives (55%) were identified using "test 1". "Test 1" produced one false positive sample (from the 20 malaria-free control) blood samples; "test 2" produced none. Kappa coefficient analysis of the results produced a value of 0.267 when microscope-positive blood smears were compared with "test 1", but 0.734 when microscope-positive blood smears were compared with the results from "test 2". Positive predictive value (PPV) and negative predictive value (NPV) were observed to be 98% and 22% respectively, for "Test 1", and 99% and 45%, for "test 2". No cross reactivity was detected with P. falciparum positive blood samples (n = 15) with either test assay.
Both tests detected P. vivax infected blood and showed no evidence of cross-reacting with P. falciparum. Further studies will need to be conducted to establish the full potential of this technique for malaria diagnostics. As well as representing a promising new cost-effective novel technique for P. vivax diagnosis and research, the method for developing this assay also highlights the potential for PAb-based strategies for diagnostics in general.
目前,用于疟原虫检测的免疫分析主要基于单克隆抗体(MAb);而多克隆抗体(PAb)开发和制造成本更低,因此应用较少。本研究描述了一种能够检测临床血液样本中的间日疟原虫乳酸脱氢酶(pLDH)的夹心 ELISA 检测方法,该方法与感染恶性疟原虫的样本无交叉反应。
从间日疟原虫 LDH 基因的不同区域产生了两种重组蛋白。然后设计了两种夹心 ELISA 检测方法:一种使用小鼠抗 LDH 1-43aa PAb 作为初级抗体(“测试 1”),另一种使用抗 LDH 35-305aa PAb 作为初级抗体(“测试 2”)。两种 ELISA 检测均使用兔抗 LDH 1-43aa PAb 作为捕获抗体。使用这两种检测方法分析了来自间日疟原虫和恶性疟原虫感染患者(经光镜确认)的血液样本。
与“测试 1”相比,“测试 2”在检测显微镜阳性血样时效果更好,可识别 154 个阳性样本中的 131 个(85%);使用“测试 1”可识别 85 个阳性(55%)。“测试 1”产生了一个假阳性样本(来自 20 个无疟疾对照)的血液样本;“测试 2”没有产生假阳性。显微镜阳性血涂片与“测试 1”相比,结果的 Kappa 系数分析值为 0.267,而显微镜阳性血涂片与“测试 2”相比,结果的 Kappa 系数分析值为 0.734。“测试 1”的阳性预测值(PPV)和阴性预测值(NPV)分别为 98%和 22%,“测试 2”的 PPV 和 NPV 分别为 99%和 45%。两种检测方法均未检测到 15 份恶性疟原虫阳性血样的交叉反应。
两种检测方法均能检测出感染间日疟原虫的血液,且与恶性疟原虫无交叉反应。需要进一步研究以确定该技术在疟疾诊断中的全部潜力。该方法不仅为间日疟原虫诊断和研究提供了一种有前途的新的经济有效的新型技术,而且还突出了基于 PAb 的策略在一般诊断中的潜力。